Trans-catheter treatment of ascending aorta aneurysms (TT3A)

​

 

Start

​

TT3A S.r.l. is developing the first on-label structural heart medical device to treat patients with ascending aorta aneurisms. Current surgical treatments of this pathology result in up to an 80% mortality rate. Therefore, our primary objective is to reduce mortality, and hospitalization time.  

 

Complete website coming soon. 

​

External venture of

​

​

​

​

 

​

Contact Antonello Fazio (CEO): af@tt3a.com

​